A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients.

This is a multicenter, open-label Phase Ib/II clinical study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of the HS-20110 combination therapies in Patients with Advanced Colorectal Cancer. "Rolling 6" design would be used to conduct dose escalation part of this study. This study consists of phase Ib and phase II. After RP2D was determined in phase Ib, then a phase II study will be conducted to further evaluate the efficacy, safety, tolerability, and PK of the HS-20110 combination therapies in Patients with mCRC.

Trial Details

NCT ID
NCT07283367
Phase
PHASE1 / PHASE2
Sponsor
Hansoh BioMedical R&D Company
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Cohort 1: HS-20110+ Bevacizumab+5-FU/leucovorin
  • Cohort 2: HS-20110+Bevacizumab+Oxaliplatin+5-FU/leucovorin
  • Cohort 3: HS-20110+Bevacizumab+Oxaliplatin+Capecitabine
Locations (sample)
  • Guangzhou, China|23.11667,113.25

Key Eligibility Criteria

  • Males or females, aged ≥ 18 years.
  • Participants with pathologically confirmed advanced Colorectal Cancer.
  • Participants have at least 1 target lesion other than CNS lesions according to RECIST 1.1.
  • MSI was tested to be non-MSI-H, and without BRAF V600E mutation.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →